ROCHE HLDG AG GEN.
Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST
Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?
Read
Commented by Nico Popp on September 23rd, 2025 | 07:00 CEST
What MASH could do for your portfolio: BioNxt, Roche, Novo Nordisk
Have you heard of MASH? The acronym stands for metabolic-associated steatohepatitis, which was previously simply called "fatty liver." Medications targeting this disease, which studies suggest affects around 6% of Americans, are being hailed as the next big trend in the biotech market. Overall, one in three overweight individuals is affected. Since many patients initially show no symptoms, MASH is considered particularly insidious. The growing discussion around the condition could turn many at-risk individuals into patients who take medication, which is excellent news for certain companies in the sector. For a small-cap stock, the hype surrounding MASH could even be transformative.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read
Commented by Nico Popp on August 25th, 2025 | 07:05 CEST
New research findings – Cell metabolism relevant in cancer: Roche, Novartis, and Vidac Pharma
What if cancer cells no longer grew uncontrollably, and we could target the metabolism of these cells directly? The so-called Warburg effect makes this possible. Discovered around 100 years ago by Otto Warburg, the effect describes the energy metabolism of cancer cells and shows that their metabolism differs from that of healthy cells. This opens up great opportunities for specific therapies in biotechnology. The theoretical assumption is that if the metabolism of cancer cells can be specifically disrupted, treatment will be targeted and free of side effects. Biotech start-up Vidac Pharma is fully committed to the Warburg effect. We explain what the Canadians are researching and why the technology could complement the offerings of several large pharmaceutical companies.
Read
Commented by Nico Popp on July 29th, 2025 | 07:20 CEST
Study reveals AI catch-up gap among pharmaceutical giants: Opportunities for Roche, Pfizer, and NetraMark?
Many observers believe that AI will revolutionize the biotech and pharmaceutical industries. A study by market researchers at Coherent Solutions now reveals the full picture: the market for biotechnology AI is projected to grow from USD 2.6 billion today to USD 12.8 billion by 2035. This corresponds to an annual growth rate of 18.8%. The report also shows how the industry's major players are preparing for the change. Since the "AI Readiness Index" calculated by the analysts paints a very complex picture, the opportunities for specialized AI investments are significant. We take a closer look at the Coherent Solutions study and introduce a business model poised to revolutionize pharmaceutical research and offer opportunities for investors.
Read
Commented by Nico Popp on May 29th, 2025 | 07:00 CEST
The next AI revolution is being spearheaded by these hidden champions: Palantir, NetraMark, Roche
Are you still working the same way you did five years ago? Let's be honest: AI has changed a lot. The opportunities are enormous, especially in biotechnology. Already in 2024, one in four venture capital dollars for AI projects went to the healthcare sector, according to Silicon Valley Bank. Although around 80% of the industry already works with AI, there is a wide range of applications, with significant differences between experiments and groundbreaking innovations. We present three AI beneficiaries from the healthcare sector and explain how investors can profit.
Read
Commented by André Will-Laudien on November 16th, 2022 | 11:27 CET
That hit home! Roche and Morphosys fail with Alzheimer's study, Bayer and Defence Therapeutics continue to rise strongly
It is common for biotech stocks to publish study results as well as figures several times a year. Since there are usually only expenses and few sales to report for these stocks fundamentally, analysts focus on the clinical successes in the way of a trial for the approval of new active substances. This can sometimes lead to erratic price movements. Roche and Morphosys suffered the same fate at the beginning of the week, with their share prices plummeting on the back of bad news. We take a look at a hot sector.
Read